Based on these findings, a phase II trial (NCT01951690) assessed the efficacy and safety of defactinib, a FAK inhibitor, in previously treated NSCLC patients, although the clinical outcome was moderate with no relation to INK4a/ARF and TP53 status [66]. The gene discussed is CDKN2A; the disease is non-small cell lung carcinoma.